Besides interferon, only two drugs—lamivudine and adefovir dipivoxil—are approved as first-
line therapy for chronic hepatitis B (CHB) in the EU [1, 2]. Each is a nucleoside or nucleotide …

The land use planning system uses regulatory power to contribute to the management of
environmental change. It is thus central to the contemporary environmental policy agenda …

Background An open-label study indicated that selective depletion of B cells with the use of
rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To …

Background Although relatively new, digital health interventions are demonstrating rapid
growth because of their ability to facilitate access and overcome issues of location, time …

Background: Angiotensin converting enzyme (ACE) 2 is a recently identified homologue of
ACE that may counterregulate the actions of angiotensin (Ang) II by facilitating its breakdown …

Background Despite rapid growth in eHealth research, there remains a lack of consistency
in defining and using terms related to eHealth. More widely cited definitions provide broad …

Objective: To determine if treatment with a B cell-targeted therapy can inhibit the progression
of structural joint damage in patients with rheumatoid arthritis (RA), exhibiting an inadequate …

Objective. To evaluate the efficacy and safety of three dosing and repeat treatment regimens
of rituximab (RTX) plus MTX in patients with active RA. Methods. Patients with active RA …

Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …

The phenylpropenamide derivatives AT-61 and AT-130 are nonnucleoside analogue
inhibitors of hepatitis B virus (HBV) replication. They inhibited the replication of wild-type …